```
WO 2005/067971
 SEQUENCE LISTING
 (110) Takeda Pharmaceutical Company Limited
 <120> A pharmaceutical composition for treating or preventing atherosclerosis
 <130> P04-251PCT
 <150> JP2004-9383
<151> 2004-01-16
 <160> 6
 <210> 1
<211> 362
<212> PRT
 <213> Homo sapience
 <400> 1
 Met Arg Arg Pro Ser Leu Leu Leu Lys Asp 11e Leu Lys Cys Thr Leu
5 10 15
Leu Val Phe Gly Val Trp Ile Leu Tyr Ile Leu Lys Leu Asn Tyr Thr
20 25 30
 Thr Glu Glu Cys Asp Met Lys Lys Met His Tyr Val Asp Pro Asp His
 Val Lys Arg Ala Gln Lys Tyr Ala Gln Gln Val Leu Gln Lys Glu Cys
 Arg Pro Lys Phe Ala Lys Thr Ser Met Ala Leu Leu Phe Glu His Arg
65 70 80
Pro Leu Ser Asp Leu Glu Tyr Tyr Ser Asn Asp Leu Phe Val Ala Val 195
Leu Phe Lys Ser Val Asp Phe Asn Trp Leu Gln Ala Met Val Lys Lys 215
Glu Thr Leu Pro Phe Trp Val Arg Leu Phe Phe Trp Lys Gln Val Ala 225
Glu Lys Ile Pro Leu Gln Pro Lys His Phe Arg Ile Leu Asn Pro Val 260
Ser Arg Phe Trp Gly Arg Asp Lys Asn Val Pro Thr Ile Gly Val Ile 275
Ala Val Val Leu Ala Thr His Leu Cys Asp Glu Val Ser Leu Ala Gly 290
Phe Gly Tyr Asp Leu Asn Gln Pro Arg Thr Pro Leu His Tyr Phe Asp 315
Ser Gln Cys Met Ala Ala Met Asn Phe Gln Thr Met His Asn Val Thr 330
Thr Glu Thr Lys Phe Leu Leu Lys Leu Val Lys Glu Gly Val Lys 345
Asp Leu Ser Gly Gly Ile Asp Arg Glu Phe
```

(210) 2 (211) 1086 (212) DNA <213> Homo sapience

Asp Leu Ser Gly Gly 11e Asp Arg Glu Phe 355

<400> 2 A400/2 at a significant and a significant and a significant at a significa WO 2005/067971 PCT/JP2005/000733

```
latagogigg acitacicco liligigoag aaggooccca aagacagiga agcigagico
aaglacgate ciccitiigg gilooggaag liciccagia aaglocagae celeliggaa cicligecag agcacgacci cocigaacae ligaaagcca agaccigicg gegeigigig
citigicag agcacgacti cotigaacat itadaagca agattigieg gogetgigig
gitaliggaa goggaggaal acigcacgga ilagaacigg gocacaccci gaaccaglic
galgiigiga laaggilaaa cagigcacca giigagggal alicagaca igiiggaaal
aaaaclacla laaggaigac ilalccagag goggaaccac igicigacci igaalallal
iccaalgaci lailigiigo igililalli aagagigiig aliicaacig golicaagca
algglaaaaa aggaaaccci gocalicigg giacgacici toiliiggaa goaggiggca
gaaaaaaloc cacigcagca aaaacaliic aggaliilga alocagilal calicaaagag
acigocilig acalocitca glacicagag octoagicaa ggilolgggg ocgagalaag
aacglococa caaloggigi caligoogii giollagooa cacalolgig ogalgaagio
                                                                                                                                 840
                                                                                                                                 900
agiliggogg gilliggala igaccicaat caaccoagaa cacciligca clacilogac
agicaalgca iggolgolal gaacilicag accalgoala algigacaac ggaaaccaag
                                                                                                                                 960
                                                                                                                               1020
 liccicitaa agciggicaa agagggagig gigaaagaic tcagiggagg caligaicgi
                                                                                                                               1080
gaallt
                                                                                                                               1086
 <210> 3
<211> 21
<212> DNA
 <213> Artificial Sequence
<220>
<223> Primer
<400> 3
laalcggaag iggcggaala c
                                                                                                                   21
<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Primer
<400> 4
cleggeccea gaaceltgae e
                                                                                                                     21
<210> 5
<211> 54
<212> DNA
<213> Artificial Sequence
<220>
<223> Nucleotide Sequence for shRNA
gaagacccag cligitaalg lgigcigicc allaacaagc igggiclict till
<210> 6
<211> 54
<212> DNA
<213> Artificial Sequence
<220>
<223> Nucleotide Sequence for shRNA
gccaalgatt igitcgliag igigcigicc taacgaacaa aicaliggci iili
```